Recent reports have shown that PPARδ agonists attenuated obesity-related diseases such as insulin resistance, diabetes and cardiovascular diseases, and regulated inflammatory cell function, which potentiated a systemic inflammatory response [18], [19], [20], [21], [22], [32], [33], [34]. The gene discussed is PPARD; the disease is obesity due to melanocortin 4 receptor deficiency.